凡利亚药品国际(NYSE:VRX)
$18.88
+0.21(+1.12%)
02-16 15:59:59(美东时间)
盘后交易18.87-0.01(-0.05%)
今开:18.67最高:19.0952周最高:24.43成交量:949.09万
昨收:18.67最低:18.6052周最低:8.31振幅:2.62%
换手率:2.72%总市值:65.08亿每股收益:3.91市盈率(静)/(TTM):-/4.77
50日均线:13.47总股本:3.49亿每股净资产:11.28市净率MRQ:1.04
200日均线:13.73机构持股:90.06股息/收益:-/-空头补回天数:1.44
简介
Valeant Pharmaceuticals International (NYSE: VRX, TSX: VRX) is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and commercialization. The focus of the company is on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of speciality chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. The company has undergone major management, operational and strategic restructurings since the 1990s when shareholders of several group units approved the merger of ICN Pharmaceuticals (founded by Milan Panić), ICN Biomedicals, SPI Pharmaceuticals and Viratek into a new global entity, ICN Pharmaceuticals, the immediate forebear of Valeant. Kinerase(R), used kinetin as active entity is one of the most famous product of this company. In May 2010, Valeant announced that they are acquiring Aton Pharmaceuticals for about $318 million.[1]
公司网站:http://www.valeant.com收起
Valeant Pharmaceuticals International (NYSE: VRX, TSX: VRX&#...展开